What is claimed is:

wherein W represents a group expressed by the following formula 2 or formula 3;

wherein each of R_1 and R_2 represents hydrogen atom. a lower alkoxy group, an alkenyloxy group, or a halogen atom:

each of R_3 and R_3 ' represents methyl group, [prenyl] <u>prenyl-CH</u>₂ group, or [geranyl] <u>qeranyl-CH</u>₂ group and when one of R_3 and R_3 ' is [prenyl] <u>prenyl-CH</u>₂ group or [geranyl] <u>qeranyl-CH</u>₂ group, another is methyl group;

X represents oxygen atom or sulfur atom;

R₁₀ represents a lower alkyl group; and

 R_{11} represents a halogen atom; and wherein each of R_4 . R_5 , and R_6 represents hydrogen atom or a lower alkyl group:

Y represents a group expressed by $-CH_2$, -O, or $-N(R_7)$, while R_7 represents a lower alkyl group, an aryl group, a carbamoyl lower alkyl group, an aralkyl group, or a heterocyclic group having 5 to 9 members; and

n represents an integer of 1 to 6.

2. An alkylenediamine derivative or a salt thereof according to claim 1. which expressed by the following formula 4.

wherein R_1 , R_2 , R_3 , R_3 , R_4 , R_5 , R_6 , and X are same as those in the above-mentioned formula 1.

3. An alkylenediamine derivative or a salt thereof according to claim 2, wherein X is oxygen atom, while R_4 , R_5 , and R_6 are hydrogen atoms.

4. An alkylenediamine derivative or a salt thereof according to claim 3, wherein R_1 and R_2 are hydrogen atoms.

5. An alkylenediamine derivative or a salt thereof according to claim 3, wherein R_1 and/or R_2 is an alkenyloxy group expressed by the following formula 5;

54

wherein each of R_b and R_b ' represents methyl group, [prenyl] $\underline{\text{prenyl-CH}}_2$ group, or [geranyl] $\underline{\text{geranyl-CH}}_2$ group and when one of R_b and R_b ' is [prenyl] $\underline{\text{prenyl-CH}}_2$ group or [geranyl] $\underline{\text{geranyl-CH}}_2$ group, another is methyl group.

6. An alkylenediamine derivative or a salt thereof according to claim 3, wherein R₁ and/or R₂ is a lower alkoxy group.
7. An alkylenediamine derivative or a salt thereof according to claim 1, which expressed by the following formula 6.

wherein R₁, R₂, R₃, R₃, R₄, R₅, R₆, and X are same as those in the above-mentioned formula 1.

8. An alkylenediamine derivative or a salt thereof according to claim 7. wherein X is oxygen atom. while R_4 , R_5 , and R_6 are hydrogen atoms.

9. An alkylenediamine derivative or a salt thereof according to claim 8, wherein R₁ and R₂ are hydrogen atoms.

10. An alkylenediamine derivative or a salt thereof according to claim 8, wherein R_1 and/or R_2 is an alkenyloxy group expressed by above-mentioned formula 5.

 An alkylenediamine derivative or a salt thereof according to claim 8, wherein R₁ and/or R₂ is a lower alkoxy group.

12. An alkylenediamine derivative or a salt thereof according to claim 1, which expressed by the following formula 7:

35 formula 7 R_1 R_2 R_3 R_4 R_5 R_7

wherein R_1 , R_2 , R_3 , R_3 , R_7 , and X are same as those in the above-mentioned formula 1.

13. An alkylenediamine derivative or a salt thereof according to claim 12. wherein X is oxygen atom. while R₁ and R₂ are hydrogen atoms. 14. An alkylenediamine derivative or a salt thereof according to claim 1. which expressed by the following formula 8;

wherein R_7 is a lower alkyl group; and R_{10} and R_{11} are same as those in the above-mentioned formula 3.

15. An alkylenediamine derivative or a salt thereof according to claim 14. wherein R_7 and R_{10} are isobutyl groups.

16. An alkylenediamine derivative or a salt thereof according to claim 14 or 15, wherein R_{11} is fluorine atom bonded to para-position.

55

17. An anti-ulcer drug comprising, as an effective ingredient, an alkylenediamine derivative or a pharmacologically acceptable salt thereof according to claim 1, together with a pharmaceutically acceptable carrier and/or adjuvant.

18. An antibacterial drug against Helicobacter pyroli comprising sas an effective ingredient, an alkylenediamine derivative or a pharmacologically acceptable salt thereof according to claim 1, together with a pharmaceutically acceptable carrier and/or adjuvant.

19. A method for the treatment of peptic ulcers in man or mammals, which comprises administering an effective amount of an alkylenediamine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.

20. A method according to claim 19, wherein said peptic ulcers are gastric ulcers in man.

21. A method for the inhibition of acid secretion in stomach of man or mammals, which comprises administering an effective amount of an alkylenediamine derivative or

56

a pharmacologically acceptable salt thereof according to claim 1 to a host.

22. A method for the inhibition of growth of Helicobacter pyroli in stomach of man or mammals, which comprises administering an effective amount of an alkylenediamine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.

or mammals. which comprises administering an effective amount of an alkylenediamine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.

24. A method according to claim 23, wherein said peptic ulcers are gastric ulcers in man.

25. An alkylenediamine derivative or a salt thereof according to claim 14. wherein R_{10} and $-O-(CH_2)-C_6H_4-R_{11}$ are at positions 3 and 4 of the benzene ring.

hybrid

112 15 X

26. An alkylenediamine derivative or a salt thereof having the following formula: